Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Valeo Pharma Inc T.VPH

Alternate Symbol(s):  T.VPH.DB | VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more

TSX:VPH - Post Discussion

Valeo Pharma Inc > VPH CEO
View:
Post by oiljack14 on Aug 17, 2020 1:33pm

VPH CEO

People need to understand that the VPH CEO is connected to big US and European Pharma and thus the regulatory bodies there as well. VPH and its share price are just reflecting an undervalued Canadian market perspective at the moment and NONE of the reality of what I hinted at or what is to come. Yes VPH IS cheap today imo. IF you understand the above!
Comment by Finallytherock on Aug 17, 2020 5:15pm
when are they listing on US exchange?
Comment by eric40 on Aug 18, 2020 8:37pm
Totally agree with you. Valeo is cheap right now considering the nature of the business (No R&D risk), the growing pipeline, an experience team that owns 75% of the cie (because they put their money on the table, not because they got free warrants), many new drugs coming to market in Q3-Q4 2020. Also huge revenu grow in the next 12 months, probably 3 to 5X with generic heparin that will start ...more